Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat

Pharmacological Reports

Volumn 60, Issue 6, 2008, Pages 789-797

  Kot, Marta ^a   Daniel, Wladyslawa A ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

8 hydroxylation; Caffeine; Coffee addiction; Cytochrome P450; Drug interactions; N demethylation; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ALLOPURINOL; ANTIFUNGAL AGENT; CAFFEINE; CARDIOVASCULAR AGENT; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C; FLUOXETINE; FLUVOXAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IDROCILAMIDE; METHYLXANTHINE; MIRTAZAPINE; N DEMETHYLASE; PARACETAMOL; PAROXETINE; PERAZINE; PHENOTHIAZINE DERIVATIVE; PROMAZINE; RISPERIDONE; SERTRALINE; BIOLOGICAL MARKER; CYTOCHROME P 450 CYP2C SUBFAMILY; CYTOCHROME P-450 CYP2C SUBFAMILY;

BIOAVAILABILITY; CALCIUM MOBILIZATION; CIGARETTE SMOKING; COFFEE; DEMETHYLATION; DIFFUSION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HYDROXYLATION; IONIZATION; METABOLISM; NEUROTRANSMISSION; NONHUMAN; OXIDATION; PHARMACODYNAMICS; REVIEW; ANIMAL; DRUG INTERACTION; LIVER; RAT; SPECIES DIFFERENCE;

ANIMALS; BIOLOGICAL MARKERS; CAFFEINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; LIVER; RATS; SPECIES SPECIFICITY;

EID: 65249119721     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Arnaud MJ: The pharmacology of caffeine. Prog Drug Res, 1987, 31, 273-313.
2. Benowitz NL, Jacob III P, Mayan H, Denaro Ch: Sympathomimetic effects of paraxanthine and caffeine in humans. Clin Pharmacol Ther, 1995, 58, 684-691.
3. Berthou F, Flinois JP, Ratanasavanh D, Beaune P, Riche C, Guillouzo A: Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos, 1991, 19, 561-567.
4. Berthou F, Goasduff T, Dreano Y, Menez JF: Caffeine increases its own metabolism through cytochrome P4501A induction in rats. Life Sci, 1995, 57, 541-549.
5. Berthou F, Guillois B, Riche C, Dreano Y, Jacqz-Aigrain E, Beaune P: Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes. Xenobiotica, 1992, 22, 671-680.
6. Bienvenu T, Pons G, Rey E, Richard M-C, d'Athis P, Arnauld MJ, Olive G: Effect of growth hormone on caffeine metabolism in hypophysectomized rats. Drug Metab Dispos, 1990, 18, 327-330.
7. Bienvenu T, Pons G, Rey E, Thiroux G, Olive G: Caffeine metabolism in liver slices during postnatal development in rats. Drug Metab Dispos, 1993, 21, 178-181.
8. Blanchard J, Sawers SJA: The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol, 1983, 24, 93-98.
9. Bonati M, Latini R, Galletti F, Young JF, Tognoni G, Garattini S: Caffeine disposition after oral doses. Clin Pharmacol Ther, 1982, 32, 98-106.
10. Bonati M, Latini R, Tognoni G, Young JF, Garattini S: Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. Drug Metab Rev, 1985, 15, 1355-1383.
11. Breimer DD: Interindividual variations in drug disposition. Clinical implications and methods of investigation. Clin Pharmacokinet, 1983, 8, 371-377.
12. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol, 1993, 45, 1211-1214.
13. Burg AW: Physiological disposition of caffeine. Drug Metab Rev, 1975, 4,199-228.
14. Busto U, Bendayan R, Sellers EM: Clinical pharmacokinetics of non-opiate abused drugs. Clin Pharmacokinet, 1989, 16, 1-26.
15. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF: Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA, 1989, 86, 7696-7700.
16. Cacciari B, Pastorin G, Spalluto G: Medicinal chemistry of A2A adenosine receptor antagonists. Curr Top Med Chem, 2003, 3, 403-411.
17. Cardinali DP: Methylxanthines: possible mechanisms of action in the brain. Trends Pharmacol Sci, 1980, 1, 405-407.
18. Carrillo JA, Benitez J: Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet, 2000, 39, 127-153.
19. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y et al.: Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A,N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5 +1 cocktail". Clin Pharmacol Ther, 2003, 74, 437-447.
20. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK et al.: Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci, 2001, 21, 1-6.
21. Chou TM, Benowitz NL: Caffeine and coffee: effects on health and cardiovascular disease. Comp Biochem Physiol, 1994, 109, 173-189.
22. Chung WG, Cha YN: Oxidation of caffeine to theobromine and theophylline is catalyzed primarily by flavin-containing monooxygenase in liver microsomes. Biochem Biophys Res Commun, 1997, 235, 685-688.
23. Chung WG, Roch HK, Kim HM, Cha YN: Involvement of CYP3A1, 2B, and [2E1] in C-8 hydroxylation and CYP1A2 and flavin-containing monooxygenase in N-demethylation of caffeine; identified by using inducer treated rat liver microsomes that are characterized with testosterone metabolic patterns. Chem Biol Int, 1998, 113, 1-14.
24. Daly JW: Mechanism of action of caffeine. In: Caffeine, Coffee, and Health. Ed. Garattini S, Raven Press Ltd., New York, 1993, 97-150.
25. Desmond PV, Patwardhan R, Parker R, Schenker S, Speeg KV Jr: Effect of cimetidine and other antihistaminics on the elimination of aminopyrine, phenacetin and caffeine. Life Sci, 1980, 26, 1261-1268.
26. Daniel WA: The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms. Expert Opin Drug Metab Toxicol, 2005, 1, 203-217.
27. Daniel WA, Kot M, Wójcikowski J: Effects of classic and newer antidepressants on the oxidation pathways of caffeine in rat liver. In vitro study. Pol J Pharmacol, 2003, 55, 1045-1053.
28. Daniel WA, Kot M, Wójcikowski J: Influence of classic and atypical neuroleptics on caffeine oxidation in rat liver microsomes. Pol J Pharmacol, 2003, 55, 1055-1061.
29. Daniel WA, Syrek M, Ryłko Z, Kot M: Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver. Pol J Pharmacol, 2001, 53, 615-621.
30. Daniel WA, Syrek M, Ryłko Z, Wójcikowski J: Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes. Pol J Pharmacol, 2001, 53, 351-357.
31. Denaro CP, Brown CR, Wilson M, Jacob 3rd P, Benowitz NL: Dose-dependency of caffeine metabolism with repeated dosing. Clin Pharmacol Ther, 1990, 48, 277-285.
32. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE: A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos, 2001, 29, 23-29.
33. Donovan JL, De Vane CL: A primer on caffeine pharmacology and its drug interactions in clinical psychopharmacology. Psychopharmacol Bull, 2001, 35, 30-48.
34. Eugster HP, Probst M, Wurgler FE, Sengstag C: Caffeine estradiol and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. Drug Metab Dispos, 1993, 21, 43-49.
35. Fisone G, Borgvist A, Usiello A: Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci, 2004, 61, 857-872.
36. Fredholm BB, Bättig K, Holmén J, Nehling A, Zvvartau EE: Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev, 1999, 51, 83-133.
37. Fredholm BB, Svenningsson P: Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities. Neurology, 2003, 61, 5-9.
38. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA: Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther, 1997, 62, 365-376.
39. Fuhr U, Doehmer J, Battula N, Wolfel C, Kudla C, Keita Y, Staib AH: Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem Pharmacol, 1992, 43, 225-235.
40. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PF: Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther, 2000, 294, 73-79.
41. Grant DM, Campbell ME, Tang BK, Kalow W: Biotransformation of caffeine by microsomes from human. Liver kinetics and inhibition studies. Biochem Pharmacol, 1987, 36, 1251-1260.
42. Gu L, Gonzalez FJ, Kalow W, Tang BK: Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics, 1992, 2, 73-77.
43. Ha HR, Chen J, Krahenbuhl S, Follath F: Biotransformation of caffeine by cDNA-expressed human cytochromes P-450. Eur J Clin Pharmacol, 1996, 49, 309-315.
44. Haduch A, Wójcikowski J, Daniel WA: The effect of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and newer antidepressant drugs on the activity and level of rat CYP3A. Eur Neuropsychopharmacol, 2006, 6, 178-186.
45. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K: Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol, 1996, 51, 73-78.
46. Jeppesen U, Loft S, Poulsen HE, Brøsen K: A fluvoxamine-caffeine interaction study. Pharmacogenetics, 1996, 6, 213-222.
47. Kalow W, Tang BK: The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther, 1993, 53, 503-514.
48. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz JS, Shader RI: Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol, 1997, 37, 693-703.
49. Kot M, Daniel WA: Effect of cytochrome P450 (CYP) inducers on caffeine metabolism in the rat. Pharmacol Rep, 2007, 59, 296-305.
50. Kot M, Daniel WA: Relative contribution of rat cytochrome P450 isoforms to the metabolism of caffeine: The pathway and concentration dependence. Biochem Pharmacol, 2008, 75, 1538-1549.
51. Kot M, Daniel WA: The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: An in vitro comparative study with cDNA-expressed P450sincluding CYP2C isoforms. Biochem Pharmacol, 2008, 76, 543-551.
52. Kot M, Wójcikowski J, Daniel WA: Caffeine metabolism during prolonged treatment of rats with antidepressant drugs. Pharmacol Rep, 2007, 6, 727-733.
53. Lee G, Dallas S, Hong M, Bendayan R: Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev, 2001, 53, 569-596.
54. Lelo A, Miners JO, Robson R, Birkett DJ: Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines. Clin Pharmacol Ther, 1986, 39, 54-59.
55. McCall AL, Millington WR, Wurtman RJ: Blood-brain barrier transport of caffeine: dose-related restriction of adenine transport. Life Sci, 1982, 31, 2709-2715.
56. Miners JO, Birkett DJ: The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen Pharmacol, 1996, 27, 245-249.
57. Morita K, Maeda Y, Masuda M, Kazusaka A, Imaoka S, Funae Y, Fujita S: Strain differences in CYP3A-mediated C-8 hydroxylation (1,3,7-trimethyluric acid formation) of caffeine in Wistar and Dark Agouti rats. Biochem Pharmacol, 1998, 55, 1405-1411.
58. Rane A, Liu Z, Henderson CJ, Wolf CR: Divergent regulation of cytochrome P450 enzymes by morphine and pethidine: a neuroendocrine mechanism? Mol Pharmacol, 1995, 47, 57-64.
59. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT: Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics, 1996, 6, 121-149.
60. Sawynok J, Yaksh TL: Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action. Pharmacol Rev, 1993, 45, 43-85.
61. Scott RJ, Palmer J, Lewis IA, Pleasance S: Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom, 1999, 13, 2305-2319.
62. Stavric B: Methylxanthines: toxicity to humans. 2. Caffeine. Food Chem Toxicol, 1988, 26, 645-662.
63. Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R et al.: Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther, 2000, 68, 375-383.
64. Sugawara M, Mochizuki T, Takekuma Y, Miyazaki K: Structure-affinity relationship in the interactions of human organic anion transporter 1 with caffeine, theophylline, theobromine and their metabolites. Biochim Biophys Acta, 2005, 1714, 85-92.
65. Tanaka E, Kurata N, Yasuhara H: How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? J Clin Pharm Ther, 2003, 28, 157-165.
66. Tassaneeyakul W, Birkett DJ, McManus ME, Tassaneeyakul W, Veronese ME, Andersson T, Tukey RH et al.: Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol, 1994, 47, 1767-1776.
67. Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, Quattrochi LC et al.: Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics, 1992, 2, 173-183.
68. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS et al: Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology (Berl), 1996, 128, 398-407.
69. Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, Schwarzschild MA: Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci, 2006, 26, 535-541.
70. Xu K, Xu YH, Chen JF, Schwarzschild MA: Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci Lett, 2002, 322, 13-16.
71. Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N, Zhou HH: Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther, 2001, 70, 455-461.